CoDa Therapeutics is a clinical-stage biotechnology company based in San Diego focused on developing novel targeted therapies that modulate gap junctions to control wound responses and reduce inflammation. Its lead candidate, Nexagon®, has completed multiple Phase 1 and Phase 2 trials in both skin and eye and has been administered to over 380 wounds on more than 180 subjects, showing safety and tolerability. The company has two open INDs and holds issued patents in the US, Europe and elsewhere, with pending applications in over a dozen additional patent families covering acute and chronic wounds, scarring, inflammation, pain, fibrosis, surgical adhesions and related combination therapies and devices. CoDa intends to use the new funding to expand late-stage clinical trials of Nexagon for additional indications, including diabetic foot ulcers. The company also executed a licensing arrangement for Nexagon IP in Russia that provides an upfront product payment and ongoing royalties based on sales. CoDa Therapeutics is a clinical-stage biopharmaceutical company developing therapeutics for wound care, inflammation and tissue repair using a platform technology called Gap Junction Modulation. The company is advancing Nexagon® and related molecules as topical therapies to address wounds that heal poorly, including venous leg and diabetic foot ulcers. CoDa has two open INDs and has completed three Phase 1 clinical trials in skin and eye, with Nexagon® shown to be safe and tolerable following administration to over 350 wounds on more than 150 subjects. The technology has issued patents in the US, Europe and elsewhere, with pending applications across more than a dozen additional patent families targeting wounds, scarring, inflammation, fibrosis, adhesions and orthopedic procedures. The company’s programs are being developed for topical application and also contemplate combination therapies and improved medical devices. The company is referenced in a San Diego dateline in the announcing article. CoDa Therapeutics is a clinical-stage biopharmaceutical company focused on treatments for wounds that do not heal properly, including venous leg and diabetic foot ulcers. Its lead product, Nexagon®, is being developed for chronic wound patients and is the focus of planned clinical work. The company is operating under an FDA‑approved IND to generate clinical data supportive of regulatory approval. CoDa intends to use the Series B proceeds to conduct a large Phase 2 multicenter venous leg ulcer trial in the United States, New Zealand and Australia. It will also continue preclinical development across its product portfolio. The company is led by CEO Bradford Duft and is based in San Diego, CA.

Total raised

$45M

Funding rounds

3

Latest round

Series B

Latest activity

Jul 2012